世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

マイクロRNA市場規模、シェア、動向分析レポート:製品・サービス別(装置、消耗品)、用途別(癌、感染症)、最終用途別、地域別、セグメント別予測、2024年~2030年


MicroRNA Market Size, Share & Trends Analysis Report By Products & Services (Instruments, Consumables), By Application (Cancer, Infectious Diseases) By End-use, By Region, And Segment Forecasts, 2024 - 2030

マイクロRNA市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界のマイクロRNA市場規模は、2024年から2030年にかけて12.87%のCAGRを記録し、2030年までに36億4000万米ドルに達すると予測... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月11日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
120 英語

1~3営業日


 

サマリー

マイクロRNA市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のマイクロRNA市場規模は、2024年から2030年にかけて12.87%のCAGRを記録し、2030年までに36億4000万米ドルに達すると予測されている。同市場の成長を後押ししているのは、新規診断検査や治療薬の開発のための研究開発イニシアティブへの多額の投資であり、臨床試験におけるマイクロRNAの統合の成功も相まって、このような状況が生まれている。現在のバイオテクノロジー産業において、バイオ医薬品部門は重要な役割を果たしている。バイオテクノロジー業界では、研究開発への支出が大幅に増加している。いくつかのバイオ医薬品会社は、RNAベースの治療薬(miRNAとsiRNA)の開発に投資している。主な企業には、Regulus Therapeutics社、Rosetta Genomics社、Alnylam Pharmaceuticals社、miRagen Therapeutics社、Mirna Therapeutics社などがある。

新しい診断テストと治療薬の開発のためのmiRNA研究開発イニシアチブにおける政府資金の増加と相まって、多額の投資が市場の成長を後押しすると予想されています。標的治療薬の開発や創薬ターゲットの同定に向けた革新的なアプローチで市場に参入してきた新規参入企業もいくつかある。例えば、2022年4月にElsevier誌に掲載された論文では、研究者チームが疾患の早期診断のための循環miRNAの臨床的価値を示す現在の大規模コホート研究の概要を提供している。

特に胸部癌のような癌細胞株において、様々なマイクロRNAの腫瘍抑制効果を調査する研究が増加していることが、マイクロRNA研究ツールに対する需要の増加を促している。さらに、miRNAベースの治療薬は様々な疾患の治療において高い可能性を示しており、絶えず進化を続けている。miRNAベースの治療薬を標的細胞に正確に送達することは、臨床応用において依然として大きな課題である。しかし、ナノ粒子ベースの送達システムなど、効率的な送達システムの最近の導入は、この課題の克服に役立つと期待されている。

マイクロRNA市場レポートハイライト

- 製品・サービス別では、単離・精製、miRNA cDNA合成、プロファイリング、局在化、定量化、機能解析など幅広いサービスを提供できるサービス分野が2023年に58.8%の高収益シェアで市場を席巻

- 用途別では、miRNAシグネチャーを採用する癌研究への投資が高いことから、2023年に癌分野が最も高い収益シェアを占めた。

- 最終用途別では、バイオテクノロジー・製薬企業分野が2023年に最も高い収益シェアで市場を支配した。これは、最先端の研究へのアクセスや大規模プロジェクトでの共同研究を可能にする研究機関との共同研究やパートナーシップを確立する能力があるためである

- 北米は、同地域の主要市場プレイヤーの存在により、2023年の世界産業で優位を占める

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Products & Service Segment
1.1.1.2. Application Segment
1.1.1.3. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. MicroRNA (miRNA) Market: Executive Summary
2.1. Market Snapshot
2.2. Products and Services Snapshots
2.3. Application and End-use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. MicroRNA (miRNA) Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Outbreak of COVID - 19
3.4.2. Recent innovation in application of miRNAs
3.4.2.1. Increased adoption for use as a biomarker
3.4.2.2. Therapeutic applications
3.4.3. High investments in miRNA R&D initiatives for development of new diagnostic tests & therapeutics
3.4.4. The success of miRNA in clinical trials
3.4.5. Technological advancements to support nucleic acid studies
3.4.6. Exponentially declining cost of sequencing
3.5. Market Restraint Analysis
3.5.1. High cost associated with microRNA kits and other products
3.5.2. Challenges in handling RNA & in-house development of assays for microRNA detection
3.5.3. Poor reproducibility of research and specificity of products
3.5.4. Limited life science research infrastructure in emerging markets
3.6. Business Environment Analysis
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTLE Analysis
3.7. COVID-19 Analysis
Chapter 4. Products & Services Estimates & Trend Analysis
4.1. MicroRNA (miRNA) Market: Products Movement Analysis
4.2. Instruments
4.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Technology
4.2.2.1. Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. Real-Time PCR
4.2.2.2.1. Real-Time PCR Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.3. Microarray
4.2.2.3.1. Microarray Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.4. NGS
4.2.2.4.1. NGS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.5. Others
4.2.2.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3. Workflow
4.2.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.2. Isolation & Purification
4.2.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.3. miRNA cDNA Synthesis
4.2.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.4. Profiling, Localization, & Qualification
4.2.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.5. Functional Analysis & Others
4.2.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.6. Others
4.2.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Consumables
4.3.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Specimen
4.3.2.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.2. Whole Blood
4.3.2.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.3. Serum
4.3.2.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.4. Plasma
4.3.2.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.5. FFPE
4.3.2.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.6. Fresh Frozen Tissue
4.3.2.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.7. Others
4.3.2.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Workflow
4.3.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.2. Isolation & Purification
4.3.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.3. miRNA cDNA Synthesis
4.3.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.4. Profiling, Localization, & Qualification
4.3.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.5. Functional Analysis & Others
4.3.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.6. Others
4.3.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Services
4.4.1. Service Type Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Isolation & Purification
4.4.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. miRNA cDNA Synthesis
4.4.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Profiling, Localization, & Qualification
4.4.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Functional Analysis
4.4.5.1. Functional Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Specimen
4.5.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Whole Blood
4.5.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Serum
4.5.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Plasma
4.5.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. FFPE
4.5.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.6. Fresh Frozen Tissue
4.5.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.7. Others
4.5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Application Estimates & Trend Analysis
5.1. MicroRNA (miRNA) Market: Application Movement Analysis
5.2. Cancer
5.2.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Infectious Diseases
5.3.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Immunological Disorder
5.4.1. Immunological Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Cardiovascular Disease
5.5.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Neurological Disease
5.6.1. Neurological Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. End-use Estimates & Trend Analysis
6.1. MicroRNA (miRNA) Market: End-use Movement Analysis
6.2. Biotechnology & Pharmaceutical Companies
6.2.1. Biotechnology & Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Academic & Government Research Institutes
6.3.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Other End-users
6.4.1. Other End-users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America MicroRNA (miRNA) Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. Target Disease Prevalence
7.2.2.5. U.S. MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Target Disease Prevalence
7.2.3.5. Canada MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. Target Disease Prevalence
7.3.2.5. UK MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Target Disease Prevalence
7.3.3.5. Germany MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.4. Spain
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. Target Disease Prevalence
7.3.4.5. Spain MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Target Disease Prevalence
7.3.5.5. France MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Target Disease Prevalence
7.3.6.5. Italy MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Target Disease Prevalence
7.3.7.5. Denmark Microrna (Mirna) Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Target Disease Prevalence
7.3.8.5. Sweden MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Target Disease Prevalence
7.3.9.5. Norway MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia-Pacific MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Target Disease Prevalence
7.4.2.5. Japan MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Target Disease Prevalence
7.4.3.5. China MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Target Disease Prevalence
7.4.4.5. India MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Target Disease Prevalence
7.4.5.5. South Korea MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Target Disease Prevalence
7.4.6.5. Thailand MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. Target Disease Prevalence
7.4.7.5. Australia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Target Disease Prevalence
7.5.2.5. Brazil MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Target Disease Prevalence
7.5.3.5. Mexico MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Target Disease Prevalence
7.5.4.5. Argentina MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Target Disease Prevalence
7.6.2.5. South Africa MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Target Disease Prevalence
7.6.3.5. Saudi Arabia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Target Disease Prevalence
7.6.4.5. UAE MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Target Disease Prevalence
7.6.5.5. Kuwait MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. Acquisition
8.2.2. Product/Service Launch
8.2.3. Partnerships/Collaborations
8.2.4. Others
8.3. Market Position Analysis, 2023
8.4. Company Profiles
8.4.1. Thermo Fisher Scientififc, Inc
8.4.1.1. Company Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. QIAGEN
8.4.2.1. Company Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Horizon Discovery Group Co.
8.4.3.1. Company Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. NanoString Technologies, Inc
8.4.4.1. Company Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Merck KGaA
8.4.5.1. Company Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Takara Bio, Inc
8.4.6.1. Company Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. LGC Limited
8.4.7.1. Company Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. BioGenex
8.4.8.1. Company Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. GeneCopoeia, Inc
8.4.9.1. Company Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. New England Biolabs
8.4.10.1. Company Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

 

ページTOPに戻る


 

Summary

MicroRNA Market Growth & Trends

The global microRNA market size is expected to reach USD 3.64 billion by 2030, registering a CAGR of 12.87% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is propelled by substantial investments in research and development initiatives for the development of novel diagnostic tests and therapeutics, coupled with the successful integration of microRNAs in clinical trials. The biopharmaceutical sector plays a significant role in the current biotechnology industry. The expenditure on R&D has significantly increased in the biotechnology industry. Several biopharmaceutical companies are investing in the development of RNA-based therapeutics (miRNAs & siRNAs). Some of the major players are Regulus Therapeutics, Rosetta Genomics, Alnylam Pharmaceuticals, miRagen Therapeutics, and Mirna Therapeutics.

The substantial investments coupled with increased government funding in miRNA R&D initiatives for the development of new diagnostic tests & therapeutics are anticipated to boost the market growth. Several new players have arrived in the market with innovative approaches for the development of targeted therapeutics and identifying drug targets. For instance, in an article published in Elsevier in April 2022, a team of researchers provided a summary of current large-cohort studies that show the clinical value of circulating miRNAs for the early diagnosis of disease.

The rising number of studies investigating the tumor-suppressive effects of various microRNAs, particularly in cancer cell lines like thoracic cancer, is driving an increased demand for microRNA research tools. Additionally, miRNA-based therapeutics have demonstrated high potential in the treatment of various diseases and are continuously evolving. Accurate delivery of miRNA-based therapeutic agents to the targeted cells remains a major challenge for clinical applications. However, the recent introduction of efficient delivery systems, such as nanoparticle-based delivery systems, is anticipated to help overcome this challenge.

MicroRNA Market Report Highlights

• Based on products & services, the services segment dominated the market with the highest revenue share of 58.8% in 2023, due to its ability to provide wide services such as isolation & purification, miRNA cDNA synthesis, profiling, localization, & quantification, functional analysis, and others

• Based on application, the cancer segment dominated the segment with the highest revenue share in 2023, due to high investments in cancer research adopting miRNA signatures

• Based on end-use, the biotechnology & pharmaceutical companies segment dominate the market with the highest revenue share in 2023, due to their ability to establish collaborations and partnerships with research institutions that allow them to access cutting-edge research and collaborate on large-scale projects

• North America dominated the global industry in 2023 owing to the presence of key market players in the region



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Products & Service Segment
1.1.1.2. Application Segment
1.1.1.3. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. MicroRNA (miRNA) Market: Executive Summary
2.1. Market Snapshot
2.2. Products and Services Snapshots
2.3. Application and End-use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. MicroRNA (miRNA) Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Outbreak of COVID - 19
3.4.2. Recent innovation in application of miRNAs
3.4.2.1. Increased adoption for use as a biomarker
3.4.2.2. Therapeutic applications
3.4.3. High investments in miRNA R&D initiatives for development of new diagnostic tests & therapeutics
3.4.4. The success of miRNA in clinical trials
3.4.5. Technological advancements to support nucleic acid studies
3.4.6. Exponentially declining cost of sequencing
3.5. Market Restraint Analysis
3.5.1. High cost associated with microRNA kits and other products
3.5.2. Challenges in handling RNA & in-house development of assays for microRNA detection
3.5.3. Poor reproducibility of research and specificity of products
3.5.4. Limited life science research infrastructure in emerging markets
3.6. Business Environment Analysis
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTLE Analysis
3.7. COVID-19 Analysis
Chapter 4. Products & Services Estimates & Trend Analysis
4.1. MicroRNA (miRNA) Market: Products Movement Analysis
4.2. Instruments
4.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Technology
4.2.2.1. Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. Real-Time PCR
4.2.2.2.1. Real-Time PCR Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.3. Microarray
4.2.2.3.1. Microarray Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.4. NGS
4.2.2.4.1. NGS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.5. Others
4.2.2.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3. Workflow
4.2.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.2. Isolation & Purification
4.2.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.3. miRNA cDNA Synthesis
4.2.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.4. Profiling, Localization, & Qualification
4.2.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.5. Functional Analysis & Others
4.2.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.3.6. Others
4.2.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Consumables
4.3.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Specimen
4.3.2.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.2. Whole Blood
4.3.2.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.3. Serum
4.3.2.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.4. Plasma
4.3.2.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.5. FFPE
4.3.2.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.6. Fresh Frozen Tissue
4.3.2.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.7. Others
4.3.2.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Workflow
4.3.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.2. Isolation & Purification
4.3.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.3. miRNA cDNA Synthesis
4.3.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.4. Profiling, Localization, & Qualification
4.3.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.5. Functional Analysis & Others
4.3.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3.6. Others
4.3.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Services
4.4.1. Service Type Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Isolation & Purification
4.4.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. miRNA cDNA Synthesis
4.4.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Profiling, Localization, & Qualification
4.4.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Functional Analysis
4.4.5.1. Functional Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Specimen
4.5.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Whole Blood
4.5.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Serum
4.5.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Plasma
4.5.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. FFPE
4.5.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.6. Fresh Frozen Tissue
4.5.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.7. Others
4.5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Application Estimates & Trend Analysis
5.1. MicroRNA (miRNA) Market: Application Movement Analysis
5.2. Cancer
5.2.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Infectious Diseases
5.3.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Immunological Disorder
5.4.1. Immunological Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Cardiovascular Disease
5.5.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Neurological Disease
5.6.1. Neurological Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. End-use Estimates & Trend Analysis
6.1. MicroRNA (miRNA) Market: End-use Movement Analysis
6.2. Biotechnology & Pharmaceutical Companies
6.2.1. Biotechnology & Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Academic & Government Research Institutes
6.3.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Other End-users
6.4.1. Other End-users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America MicroRNA (miRNA) Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. Target Disease Prevalence
7.2.2.5. U.S. MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Target Disease Prevalence
7.2.3.5. Canada MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. Target Disease Prevalence
7.3.2.5. UK MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Target Disease Prevalence
7.3.3.5. Germany MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.4. Spain
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. Target Disease Prevalence
7.3.4.5. Spain MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Target Disease Prevalence
7.3.5.5. France MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Target Disease Prevalence
7.3.6.5. Italy MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Target Disease Prevalence
7.3.7.5. Denmark Microrna (Mirna) Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Target Disease Prevalence
7.3.8.5. Sweden MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Target Disease Prevalence
7.3.9.5. Norway MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia-Pacific MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Target Disease Prevalence
7.4.2.5. Japan MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Target Disease Prevalence
7.4.3.5. China MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Target Disease Prevalence
7.4.4.5. India MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Target Disease Prevalence
7.4.5.5. South Korea MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Target Disease Prevalence
7.4.6.5. Thailand MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. Target Disease Prevalence
7.4.7.5. Australia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Target Disease Prevalence
7.5.2.5. Brazil MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Target Disease Prevalence
7.5.3.5. Mexico MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Target Disease Prevalence
7.5.4.5. Argentina MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Target Disease Prevalence
7.6.2.5. South Africa MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Target Disease Prevalence
7.6.3.5. Saudi Arabia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Target Disease Prevalence
7.6.4.5. UAE MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Target Disease Prevalence
7.6.5.5. Kuwait MicroRNA (miRNA) Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. Acquisition
8.2.2. Product/Service Launch
8.2.3. Partnerships/Collaborations
8.2.4. Others
8.3. Market Position Analysis, 2023
8.4. Company Profiles
8.4.1. Thermo Fisher Scientififc, Inc
8.4.1.1. Company Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. QIAGEN
8.4.2.1. Company Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Horizon Discovery Group Co.
8.4.3.1. Company Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. NanoString Technologies, Inc
8.4.4.1. Company Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Merck KGaA
8.4.5.1. Company Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Takara Bio, Inc
8.4.6.1. Company Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. LGC Limited
8.4.7.1. Company Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. BioGenex
8.4.8.1. Company Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. GeneCopoeia, Inc
8.4.9.1. Company Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. New England Biolabs
8.4.10.1. Company Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Grand View Research社の生物分野での最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る